2025-2034 Pulmonary Drugs Market Roadmap: Insights for Competitive Advantage

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Pulmonary Drugs Market Size By 2025?
The market size of pulmonary drugs has shown consistent growth over the recent years. It's projected to escalate from $54.28 billion in 2024, reaching $56.98 billion in 2025 with a Compound Annual Growth Rate (CAGR) pegged at 5.0%. Reasons contributing to this growth during the historic period include a rising number of respiratory ailments, an uptick in smoking incidences, growth of the elderly population, enhanced accessibility to healthcare, and a notable increase in pollution levels.

How Big Is the Pulmonary Drugs Market Size Expected to Grow by 2029?
The market size for pulmonary drugs is anticipated to experience robust growth in the forthcoming years, reaching "$70.35 billion by 2029 with a compound annual growth rate (CAGR) of 5.4%. This growth during the forecast period is expected to be propelled by factors such as the expansion of healthcare structures, the escalation of cardiovascular disease cases, the growth of homecare remedies, increased knowledge about pulmonary diseases, and a surge in asthma prevalence. Key trends to watch out for in the forecast period encompass advancements in technology, the use of artificial intelligence in drug discovery, the adoption of smart inhalers, formulations based on nanotechnology, and advancements in gene therapy.

View the full report here:
https://www.thebusinessresearchcompany.com/report/pulmonary-drugs-global-market-report

Which Key Market Drivers Powering Pulmonary Drugs Market Expansion and Growth?
With respiratory disorders on the rise, the pulmonary drugs market is anticipated to see significant growth. Medical conditions impacting the lungs and airways, inhibiting regular respiration and oxygen transfer, are known as respiratory disorders. The increasing incidents of smoking are resulting in lung damage and chronic diseases, contributing to the climbed rate of these disorders. Pulmonary medications are paramount in managing these conditions as they enhance lung functionality, alleviate inflammation, and remove airway blocks which paves way for natural breathing. Specifically, data from the Bureau of Labor Statistics revealed that the sickness rate among private businesses in 2022 escalated to 45.2 cases per 10,000 FTE employees, a hike from 37.7 cases the previous year in 2021. This upsurge is largely due to an increased prevalence of respiratory ailments, rising from 27.8 cases per 10,000 FTE employees in 2021 to 35.8 cases in 2022. Hence, these escalating respiratory disorders are spurring the growth of the pulmonary drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23489&type=smp

Which Emerging Trends Are Transforming the Pulmonary Drugs Market in 2025?
In an effort to improve treatment effectiveness, patient compliance, and simplify medication routines for enhanced disease control, key players in the pulmonary drugs market are concentrating their efforts on creating innovative therapeutic strategies such as single-inhaler triple therapy (SITT). SITT is an approach that consolidates three varying medications into a solitary inhaler for managing chronic respiratory conditions like chronic obstructive pulmonary disease (COPD) in a more efficient manner. GlaxoSmithKline Pharmaceuticals Limited, an Indian pharmaceutical corporation, introduced India's premier single-inhaler triple therapy (SITT) for COPD patients in April 2022, named Trelegy Ellipta. This therapy mixes fluticasone furoate, umeclidinium, and vilanterol to boost lung function and minimize symptom outbursts. The Ellipta inhaler's innovativeness ensures precise dosing and raises patient compliance compared to multiple-inhaler treatments. Given the vast COPD patient population in India, exceeding 100 million, this introduction aims to streamline treatment and enhance patient results.

What Are the Emerging Segments in the Pulmonary Drugs Market?
The pulmonary drugs market covered in this report is segmented -

1) By Drug Class: Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Other Drug Classes
2) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Other Indications
3) By Distribution Channel: Retail Pharmacies, Online Pharmacies, Hospitals Pharmacies

Subsegments:
1) By Inhaled Corticosteroids: Beclomethasone, Budesonide, Fluticasone, Mometasone, Ciclesonide
2) By Long-Acting Beta-2 Agonists: Salmeterol, Formoterol, Indacaterol, Olodaterol, Vilanterol
3) By Antihistamines: Cetirizine, Loratadine, Fexofenadine, Diphenhydramine, Levocetirizine
4) By Vasodilators: Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors, Prostacyclin Analogues
5) By Short-Acting Beta-2 Agonists (SABA): Albuterol, Levalbuterol, Terbutaline, Fenoterol, Pirbuterol
6) By Other Drug Classes: Monoclonal Antibodies, Enzymes, Antibiotics, Antileukotrienes

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=23489&type=smp

Who Are the Global Leaders in the Pulmonary Drugs Market?
Major companies operating in the pulmonary drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Limited, AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Grifols S.A., Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Pharmaceuticals Inc., United Therapeutics Corporation, Mallinckrodt Pharmaceuticals plc, Glenmark Pharmaceuticals Limited, Circassia Pharmaceuticals plc

Which are the Top Profitable Regional Markets for the Pulmonary Drugs Industry?
North America was the largest region in the pulmonary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23489

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.